BioWorld

Jan. 6, 2006

Nuvelo Surges On Alfimeprase Agreement For Up To $385M

Nuvelo Inc.'s stock benefitted Thursday when the company entered a collaboration with pharmaceutical giant Bayer HealthCare AG to develop and commercialize the cardiovascular drug alfimeprase. (BioWorld Today) Read More

Diversa Cuts Staff, Focuses Efforts On Late-Stage Work

AVEO In-Licenses Kinase Inhibitor From Mitsubishi

NeoPharm Raising $35.7M; Pivotal Phase III Goes On

Innovive Adding Dual Inhibitor To Oncology Pipeline For CML

Appointments And Advancements

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 23, 2026.

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...